Introduction
Murine leukemia virus (MLV)-based vector is one of the frequently used gene delivery vehicle, being employed in approximately a quarter of the approved clinical protocols worldwide (http://www.wiley.co.uk/ genmed/clinical). However, there are still problems with the retroviral vectors used currently in the clinical setting. In particular, the issue of safety has often been raised, mainly because of the possibility of generation of replication-competent retroviruses and unexpected activation of genes adjacent to the viral integral sites. In this regard, it should be noted that development of leukemia manifesting clonal integration of the retrovirus into a proto-oncogene LMO2 was observed in two SCID-X1 patients in a French trial. 1 Another important problem to overcome is the immunogenicity of the retroviral vectors themselves, that could induce humoral and cellular immune responses in the hosts that eventually diminish effective gene transfer. [2] [3] [4] [5] [6] [7] [8] [9] [10] Most retroviral vectors so far reported contain retroviral coding sequences, such as the 5 0 end of the gag gene to increase their packaging efficiency. [11] [12] [13] [14] Because a number of potential start codons, such as ATG or CTG, remain intact in the extended packaging sequences in most of the retroviral vectors, 12 polypeptides translated from them may induce immune responses, in addition to those against transgene products such as a-L-iduronidase 6 or selectable markers (eg, neomycin, 15 hygromycin and/or herpes virus thymidine kinase 16, 17 ). However, it still needs to be determined whether or not the products encoded by the retroviral vector backbone sequences are immunogenic in humans.
The LZRSpBMN, 18 Molony MLV-derived retroviral vector used in this study, contains full-length long terminal repeats (LTRs) and an extended packaging sequence with a portion of the pol gene derived from MFG retroviral vectors, 19 which have been used in a number of clinical trials, including a French trial for SCID-X1. 1 The extended packaging sequence is made by a combination of the original packaging signal and 426 bp of the 5 0 end of the gag gene, followed by 375 bp of the 3 0 end of the pol gene which harbors the splicing acceptor sites.
14 In wild-type MLV, Gag and Pol proteins are translated from the unspliced mRNA. The MFG vector still expresses a significant amount of the unspliced messages. 20 There are many potential start codons within the extended packaging sequence, such as CTG of gPr80 gag and ATG of Pr65 gag . Moreover, some (cryptic) polypeptides may be translated from genomic (unspliced) mRNA. Thus, it is possible that these products may give rise to host immune responses which could lead to rapid clearance of retrovirally transduced cells after in vivo infusion.
In this study, we demonstrated that human cytotoxic T-lymphocyte (CTL) clones recognizing epitopes derived from the protein encoded by the retroviral vector backbone. Two identified CTL epitopes were located in the gag gene, and the other epitope was in the artificial polypeptide joining the gag and pol sequences.
Results
In a previous study, we achieved efficient generation of cytomegalovirus (CMV)-pp65-specific CTL lines from CMV-seropositive donors using CD40-activated B (CD40-B) cells retrovirally transduced with the CMV-pp65 gene as antigen-presenting cells (APC). 21, 22 With all of eight CMV-seronegative donors, however, we failed to generate pp65-specific CTL lines. Thus, to enhance the efficiency of induction of pp65-specific CTLs, we cultured CD8 T cells in the presence of interleukin-12, which is known to be an immunostimulatory cytokine. In fact, CTL lines were then induced in seven out of the eight seronegative donors. Unexpectedly, however, four of them showed cytotoxicity against not only pp65-transduced EBV-transformed lymphoblastic cell lines (LCLs) but also LCLs transduced with an irrelevant antigen, EGFP, whereas untransduced LCLs were not lysed ( Figure 1a) . These results suggest that the CTL lines were specific for viral-related antigens generated in the retrovirally transduced cells. These interesting findings prompted us to identify the antigens recognized. By limiting dilution, we established two CTL clones, 8C7 and 9C10, from a CMV-seronegative donor and their specificity was evaluated. IFN-g ELISPOT assays revealed that clones 8C7 and 9C10 recognized 293T cells transfected with the retroviral vector, LZRSpBMN, in combination with HLA-B*4403 and -B*4601, respectively (Figure 1b) , indicating that the antigens recognized by the CTL clones were indeed derived from the retroviral vector.
Because, in the retroviral vector we used, 5 0 LTR is active as an RNA polymerase II promoter, and the start codons of gPr80 gag and Pr65 gag in the extended packaging signal are not mutated, it is possible that several different polypeptides may be translated from the genomic mRNA. 20 Thus, we subcloned the region spanning the start codon of gPr80 gag through a unique BamHI site of the vector into a mammalian expression vector, termed pcDNA3-gPr80, to determine which polypeptides translated from the extended packaging signal are antigenic. Both CTL clones could recognize 293T cells transfected with both pcDNA3-gPr80 and restricting HLA alleles, indicating that the region contains the CTL epitopes.
For their identification, linear expression fragments encoding serial C-terminal truncations of the region were constructed and expressed in 293T cells (Table 1) , as previously reported. 22 The HLA-B*4403-restricted CTL clone 8C7 recognized transfectants expressing aa 1-169 or longer, but not 1-138, indicating that the epitope fully or partially lies between aa 139 and aa 169. With the aid of a computer algorithm, 23 peptides presented by HLA-B*4403 within the localized region were predicted ( Table  2) . Because a fragment encoding a decamer peptide, In the case of CTL clone 9C10, the same region was recognized ( Table 1 ). The binding motif for HLA-B*4601 has been reported as Met at position 2 and Tyr or Phe at the C-terminus, 24 but peptide binding prediction by the computer algorithm for HLA-B*4601 is not currently available. Because there were four Phe, but no Met and Tyr within the region, we generated linear expression fragments encoding four kinds of decamer peptides ending at each Phe. A fragment encoding TFCSAEWPTF (aa 137-146) was well recognized by the CTL clone 9C10. As shown in Figure 2b , C-terminal deletion affected the recognition by the CTL clone, whereas N-terminal deletions did not. By titration assay with synthetic peptides (data not shown), a nonamer peptide, FCSAEWPTF (aa 138-146), was identified as the minimal epitope presented by HLA-B*4601.
Similarly, CTL clones specific for retrovirally transduced cells were obtained by stimulation of CD8 T cells from a cervical cancer patient using HPV16-E6 and E7 transduced CD40-B cells as APC. One of the CTL clones, 3B4, was restricted by HLA-B*3501 and recognized 293T cells transfected with pcDNA3-gPr80 and HLA-B*3501 ( Figure 3 ). With the linear expression fragments of serial C-terminal truncations, a region containing the CTL epitope was localized within aa 237-331 (Table 1) . Several HLA-B*3501-restricting peptides within this region were predicted by the computer algorithm (Table 2) . Among them, the CTL clone 3B4 well recognized a decamer, APIWPYEILY (aa 240-249, Figure 3b ), which interestingly was composed of the artificial junctional region of gag and pol (Figure 4) . 18 
Discussion
In the present study, we demonstrated that human CTLs specific for HLA class I-bound peptides encoded by retroviral vector backbone sequences can readily be induced in vitro. To the best of our knowledge, this is the first identification of epitopes derived from residual retroviral coding sequences rather than inserted cDNAs recognized by human cells. In mice, it has been already shown that Moloney MLV-or other retrovirus-induced tumor cell lines, such as RMA and FBL-3, are lysed by CTL responses, and that the immunodominant epitope of Moloney MLV restricted by H-2D b is located within the gag leader protein encoded in the extended packaging sequence of the retroviral vector. 25 With regard to humoral immune responses, induction of anti-MLV antibodies has been reported in mice and nonhuman primates 5 as well as in patients treated for brain tumors with murine retroviral vector producer cells. 26 Thus, it is likely that the immune responses against not only inserted gene products but also retroviral coding sequence products can similarly be induced in vivo, with vector-based treatment of patients.
The immunogenicity of transferred gene products also remains one obstacle in the development of efficient clinical gene therapy protocols, particularly when introducing artificial or xenogenic sequences. Various attempts have been made to overcome this problem, including asanguineous perfusion after infection of retroviral vectors in liver transplant cases, 4 transplantation of transduced hematopoietic stem cells 7, 27, 28 or infusion of antigen-specific regulatory T cells, 29 with the aim of establishing immune tolerance to transgene products. In the French clinical trial for the X-linked form of SCID, 1 which is the first recorded case of a therapeutic effect of retroviral gene therapy in humans, the transferred gene is expressed in the patients long term. Immune responses against the transferred common g-chain gene or MFG-based retroviral vector coding sequences have not been reported so far, which may be due to relative immunodeficiency in these X-SCID patients. Retention of retroviral sequences may also result in generation of replication-competent retroviruses as a result of homologous recombination. 11 Substitution of the packaging sequence of MLV-based vectors by sequences derived from other viruses has been successfully employed without loss of the transduction efficiency. 30 Indeed, attempts have been made to remove all ATG start codons without losing efficient viral packaging.
12,14 These approaches may be able to provide more effective ways to avoid immunogenicity of retroviral vectors and also generation of replication-competent retroviruses. Finally, the present identification of an immunogenic HLA-B35-restricted peptide derived from the gag-pol junctional region may be of clinical significance because vectors encoding various chimeric molecules are currently often used.
In conclusion, peptides encoded by the retroviral vector backbone sequence show potent immunogenicity in vitro so as to induce CTL responses. Thus, it is likely that they may also stimulate CTL responses in vivo, leading to rapid clearance of retrovirally transduced cells and resulting in adverse effects. We should take into consideration this problem by actively monitoring immune responses in retroviral vector-mediated gene therapies.
Materials and methods

Donors and cells
Peripheral blood samples were obtained from CMVseronegative healthy donors or cervical cancer patients after we obtained informed consent under a protocol approved by the Institutional Review Board of Aichi Cancer Center according to the Declaration of Helsinki. HLA typing was carried out at The HLA Laboratory (Kyoto, Japan). Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood by centrifugation on a Ficoll (Amersham Biosciences, Uppsala, Sweden) density gradient, and CD8-positive and -negative fractions were separated using CD8 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) and cryopreserved until use. 
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Plasmids and synthetic peptides
Plasmids, pcDNA3-pp65, pcDNA3-EGFP, pcDNA3.1.
(Invitrogen, Tokyo, Japan) encoding HLA-class I cDNA, LZRSpBMN-pp65 (the backbone plasmid, LZRSpBMN-Z was kindly provided by Dr G Nolan, Stanford University, Stanford, CA, USA), pLBPC-pp65 and pLBPC-EGFP were constructed as previously described. 21, 31 All peptides were purchased from Toray Research Center (Tokyo, Japan). HPV16-E6 or -E7 gene (kindly provided by Dr T Kiyono, National Cancer Center Research Institute, Tokyo, Japan) was inserted into the LZRSpBMN vector (LZRSpBMN-E6 or LZRSpBMN-E7, respectively) and the pLBPC vector (pLBPC-E6 or pLBPC-E7, respectively). To generate pcDNA3-gPr80, the region spanning the start codon of gPr80gag through a unique BamHI site of the LZRSpBMN-Z vector ( Figure  4a ) was inserted into multiple cloning site of the pcDNA3.1 vector.
Generation of CD40-activated B cells and LCLs
CD40-B cells were generated as previously described. 21, 32, 33 In brief, a thawed CD8-negative fraction of PBMCs was cultured on a g-irradiated (96 Gy) human CD40L-transfected NIH3T3 cell line 34 (t-CD40L; kindly provided by Dr Gordon Freeman, Dana-Farber Cancer Institute, Boston, MA, USA) in the presence of IL-4 (4 ng/ml; Ono Pharmaceutical, Osaka, Japan) and cyclosporin A (CsA, 0.7 mg/ml; Sandoz, Basel, Switzerland) in 2 ml of Iscove's modified Dulbecco's medium (Invitrogen) supplemented with 10% pooled human serum. The expanding cells were transferred onto freshly prepared t-CD40L cells and fed with cytokine-replenished medium without CsA every 3-4 days. LCLs were established from the CD40-B cells with supernatant of an EBV producing cell line (B95-8, ATCC, Manassas, VA, USA) in RPMI 1640 (Invitrogen) supplemented with 10% fetal calf serum (FCS; IBL, Takasaki, Japan), referred to as RPMI-10.
Retroviral transduction of CD40-B cells and LCLs
Retroviral transduction was conducted as previously described. 21 In brief, the retroviral construct, for example, LZRSpBMN-pp65, was packaged in the Phoenix GALV cell line 35 (a gift from H-P Kiem, Fred Hutchinson Cancer Research Center, and from G Nolan, Stanford University, Stanford, CA, USA) using FuGENE 6 (Roche Diagnostics, Mannheim, Germany). CD40-B cells and LCLs were infected with the retroviral supernatant in the presence of 10 mg/ml polybrene (Sigma, Chicago, IL, USA), spun at 1000 g for 1 h at 321C, and incubated. Two days after, LCLs transduced with CMV-pp65 (LCL/pp65), HPV16-E6 (LCL/E6), HPV16-E7 (LCL/E7), EGFP (LCL/EGFP) were selected in the presence of puromycin (0.7 mg/ml; Edge Biosystems, Gaithersburg, MD, USA). Transduction efficiency were assessed as previously described. 21 Generation of antigen-specific CTL lines using retrovirally transduced CD40-B cells Thawed CD8-positive cells (1 Â 10 6 ) were cocultured with g-irradiated (33 Gy) autologous retrovirus-transduced CD40-B (CD40-B/pp65) cells (1 Â 10 6 ) in 2 ml RPMI 1640 supplemented with 10% pooled human serum, recombinant human IL-7 (50 U/ml; Genzyme, Cambridge, MA, USA) and IL-12 (5 ng/ml; R&D systems, Minneapolis, MN, USA) at 371C in 5% CO 2 . On days 7 and 14, CD8 + cells were restimulated, and 1 day after each stimulation, recombinant human IL-2 (Chiron, Emeryville, CA, USA) was added to the cultures at the final concentration of 20 U/ml. If necessary, rapidly growing cells were split into 2-3 wells and fed with fresh media containing 20 U/ml IL-2.
Epitope selection and construction of linear expression fragments
Linear expression fragments encoding various C-terminus truncated gag-pol gene of LZRSpBMN (Table 1) or various peptides (Table 2, Figure 2 ) were generated using an overlapping PCR method. 22 Targeted region-specific 5 0 and 3 0 primers incorporating additional sequences (single-and double-underlined, see below) were designed, for example, 5 0 primer, TCGGATCCACCATGCTGA CGAGTTCGGAAC (30 bp) and 3 0 primer, GACTCGAGC GCTATAAGATCTCATATGGCC (30 bp) for the fragment encoding aa 1-248, and used for PCR (KOD Plus; Toyobo, Osaka, Japan) with a template retroviral vector, LZRSpBMN. The CMV promoter (P CMV ) and BGH CTLs against retroviral vectors E Kondo et al polyadenylation signal (pA) were independently amplified from pcDNA3.1 by PCR using the following primers: 5 0 P CMV , CTTAGGGTTAGGCGTTTTGC; 3 0 P CMV , NNCATGGTGGATCCGAGCTCGGTA; 5 0 pA, NNTAGC GCTCGAGTCTAGAGGG; 3 0 pA, GGTTCTTTCCGCCTC AGAAG; 'N' means a mixture of A/C/T/G). The 3 0 P CMV and 5 0 pA primers contained overlapping sequences (underlined) with the 5 0 primer and 3 0 primer, respectively, of the targeted region. The three PCR products, P CMV , the targeted region, and pA, were conjugated by second PCR using primers, 5 0 P CMV and 3 0 pA. Each linear expression fragment was termed '1-XXX' (C-terminus truncated gag-pol gene; 'XXX' indicates the amino-acid positions of the C-terminus) or peptide sequence.
ELISPOT assays
ELISPOT assays were performed as described earlier. 21, 22 In brief, a MultiScreen-HA plate (MAHA S4510, Millipore, Bedford, MA, USA) was coated with anti-human IFN-g mAb (M700A; Endogen, Woburn, MA, USA) and used as an ELISPOT plate. 293T cells were cotransfected with plasmids encoding each of the individual donor's HLA-class I alleles and either antigen encoding plasmids or PCR products of the linear expression fragment by TransIT-293 (Mirus, Madison, WI, USA), and used as stimulator cells after 2 days. The transfected 293T cells, LCLs or retrovirally transduced LCLs were mixed with 10 3 or more effector cells from the CTL lines or clones generated. After cells had been incubated in 200 ml RPMI-10 in a round-bottom 96-well plate (Costar Corning, Cambridge, MA, USA) for 4 h, all the aliquots were transferred into an ELISPOT plate and incubated for an additional 16 h. To visualize spots, a biotin-labeled anti-human IFN-g antibody (M701B; 1 mg/ml, Endogen), streptavidin-alkaline phosphatase (Biosource International, Camarillo, CA, USA), and substrate were used. Spots were counted after computerized visualization using a scanner (Canon, Tokyo, Japan).
Chromium release assays
LCLs or retrovirally transduced LCLs were labeled in 100 ml RPMI-10 with 3.7 MBq
51
Cr for 1 h at 371C. After 4 h incubation with effector cells, supernatants were counted in a gamma counter. The percentage of specific lysis was calculated as follows: [(experimental release À spontaneous release)/(maximum release -spontaneous release)] Â 100.
